Literature DB >> 21450507

Mortality in spondylarthritis.

Clément Prati1, Pascal Claudepierre, Thao Pham, Daniel Wendling.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that can lead to chronic pain in axial and peripheral joints and to functional impairments after several years. Excess mortality has been reported in patients with AS. We reviewed recent studies of patients with AS who were treated and monitored according to the improved methods developed in the past few years, without radiation therapy. Our results do not support excess mortality in these patients. Long-term follow-up data from patients enrolled in biologics registries will provide additional information. Cardiovascular disease is the leading cause of death in patients with AS, as in the general population. However, the cardiovascular mortality rate may be slightly increased in patients with AS, probably as a result of dyslipidemia and early endothelial dysfunction. Similarly, and as expected, there is excess mortality related to the spinal disease itself and to renal and gastrointestinal disease. More surprisingly, alcohol abuse and injury or suicide cause excess mortality compared to the general population. In the absence of radiation or radium-224 therapy, and regardless of the other treatments used, the evidence does not support an increased rate of lymphoma or other malignancies compared to the general population. In this review, we discuss the causes and rates of mortality in patients with AS.
Copyright © 2011 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21450507     DOI: 10.1016/j.jbspin.2011.02.012

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  9 in total

1.  Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study.

Authors:  Kerry A Wright; Cynthia S Crowson; Clement J Michet; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

Review 2.  [Spondyloarthritis in childhood and adulthood].

Authors:  Toni Hospach; Gerd Horneff; Denis Poddubnyy
Journal:  Z Rheumatol       Date:  2022-01-05       Impact factor: 1.372

3.  Endothelial dysfunction and increased carotid intima-media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors.

Authors:  Aicha Ben Tekaya; Seif Boukriba; Ahmed Fendri; Leila Rouached; Olfa Saidane; Selma Bouden; Rawdha Tekaya; Kamel Ben Salem; Ines Mahmoud; Mizouni Habiba; Leila Abdelmoula
Journal:  RMD Open       Date:  2022-07

Review 4.  Comorbidities in Spondyloarthritis.

Authors:  Anna Moltó; Elena Nikiphorou
Journal:  Front Med (Lausanne)       Date:  2018-03-12

5.  Association of circulating calprotectin with lipid profile in axial spondyloarthritis.

Authors:  Fernanda Genre; Javier Rueda-Gotor; Sara Remuzgo-Martínez; Alfonso Corrales; Verónica Mijares; Rosa Expósito; Cristina Mata; Virginia Portilla; Ricardo Blanco; José Luis Hernández; Javier Llorca; Oreste Gualillo; Raquel López-Mejías; Miguel A González-Gay
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

Review 6.  Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis.

Authors:  Rebecca S Y Wong
Journal:  Adv Pharmacol Sci       Date:  2019-01-29

7.  HLA-B27 Negativity Is Associated With Renal Function Decline in Patients With Ankylosing Spondylitis and Secondary IgA Nephropathy.

Authors:  Ti Zhang; Fan Yang; Ke Zuo; Jinquan Wang; Zhen Cheng; Jiong Zhang
Journal:  Front Med (Lausanne)       Date:  2020-04-07

8.  Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study.

Authors:  Helena Forsblad-d'Elia; Hanna Wallberg; Eva Klingberg; Hans Carlsten; Lennart Bergfeldt
Journal:  BMC Musculoskelet Disord       Date:  2013-08-12       Impact factor: 2.362

9.  All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019.

Authors:  Vasiliki-Kalliopi Bournia; George E Fragoulis; Panagiota Mitrou; Konstantinos Mathioudakis; Anastasios Tsolakidis; George Konstantonis; Georgia Vourli; Dimitrios Paraskevis; Maria G Tektonidou; Petros P Sfikakis
Journal:  RMD Open       Date:  2021-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.